EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Endogenous Glucose Production in Patients With Glycogen Storage Disease Type Ia Estimated by Oral D-[6,6-2H2]-glucose

Alessandro Rossi, Maaike H Oosterveer, Theo H van Dijk, Aycha Bleeker, Martijn Koehorst, David A Weinstein, Barbara M Bakker, Terry G J Derks iD

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgad537 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Alessandro Rossi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Section of Metabolic Diseases, Beatrix Children's Hospital, University of Groningen, University Medical Center Groningen, 9…. Hauptthemen laut MEDLINE: Glucose, Glycogen Storage Disease Type I. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ultragenyx Pharmaceutical Inc, University of Groningen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Glycogen storage disease type Ia (GSDIa) is an inborn metabolic disorder characterized by impaired endogenous glucose production (EGP). Monitoring of patients with GSDIa is prioritized because of ongoing treatment developments. Stable isotope tracers may enable reliable EGP monitoring.

Objective

The aim of this study was to prospectively assess the rate of appearance of endogenous glucose into the bloodstream (Ra) in patients with GSDIa after a single oral D-[6,6-2H2]-glucose dose.

Methods

Ten adult patients with GSDIa and 10 age-, sex-, and body mass index–matched healthy volunteers (HVs) were enrolled. For each participant, 3 oral glucose tracer tests were performed: (1) preprandial/fasted, (2) postprandial, and (3) randomly fed states. Dried blood spots were collected before D-[6,6-2H2]-glucose administration and 10, 20, 30, 40, 50, 60, 75, 90, and 120 minutes thereafter.

Results

Glucose Ra in fasted HVs was consistent with previously reported data. The time-averaged glucose Ra was significantly higher in (1) preprandial/fasted patients with GSDIa than HV and (2) postprandial HV compared with fasted HV(P < .05). A progressive decrease in glucose Ra was observed in preprandial/fasted patients with GSDIa; the change in glucose Ra time-course was directly correlated with the change in capillary glucose (P < .05).

Conclusion

This is the first study to quantify glucose Ra in patients with GSDIa using oral D-[6,6-2H2] glucose. The test can reliably estimate EGP under conditions in which fasting tolerance is unaffected but does not discriminate between relative contributions of EGP (eg, liver, kidney) and exogenous sources (eg, dietary cornstarch). Future application is warranted for longitudinal monitoring after novel genome based treatments in patients with GSDIa in whom nocturnal dietary management can be discontinued.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucoseGlycogen Storage Disease Type IAdultHumansLiverGlucose-6-PhosphataseBlood Glucose

Stichwörter der Autor:innen

dietglycogen storage disease type Iamonitoringprecision medicinestable isotopes

Substanzen

GlucoseGlucose-6-PhosphataseBlood Glucose

Autor:innen und Institutionen

  • Department of Pediatrics, Section of Metabolic Diseases, Beatrix Children's Hospital, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
  • Department of Translational Medicine, Section of Pediatrics, University of Naples "Federico II", 80131 Naples, Italy.
  • Department of Pediatrics, Laboratory of Pediatrics, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
  • Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
  • Department of Pediatrics, University of Connecticut School of Medicine, Farmington, CT, USA.

ORCID-Profile: Terry G J Derks

Förderung

  • Ultragenyx Pharmaceutical Inc
  • University of Groningen

Zitieren

APA

Rossi, A., Oosterveer, M. H., van Dijk, T. H., Bleeker, A., Koehorst, M., Weinstein, D. A., Bakker, B. M., & Derks, T. G. J. (2024). Endogenous Glucose Production in Patients With Glycogen Storage Disease Type Ia Estimated by Oral D-[6,6-2H2]-glucose. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad537

Vancouver

Rossi A, Oosterveer MH, van Dijk TH, Bleeker A, Koehorst M, Weinstein DA, et al. Endogenous Glucose Production in Patients With Glycogen Storage Disease Type Ia Estimated by Oral D-[6,6-2H2]-glucose. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad537

BibTeX
@article{Rossi2024,
  author = {Rossi, Alessandro and Oosterveer, Maaike H and van Dijk, Theo H and Bleeker, Aycha and Koehorst, Martijn and Weinstein, David A and Bakker, Barbara M and Derks, Terry G J},
  title = {Endogenous Glucose Production in Patients With Glycogen Storage Disease Type Ia Estimated by Oral D-[6,6-2H2]-glucose},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgad537}
}
Kostenlos starten →